No­var­tis joins forces with LA tech com­pa­ny Sci­ence 37 to launch vir­tu­al clin­i­cal tri­als

No­var­tis is pair­ing up with a Los An­ge­les tech com­pa­ny to launch 10 vir­tu­al clin­i­cal tri­als, in which pa­tients will use cell phones to par­tic­i­pate rather than trav­el­ing to hos­pi­tals and clin­ics.

The phar­ma gi­ant is us­ing tech made by Sci­ence 37, a soft­ware com­pa­ny that con­nects pa­tients to re­searchers via mo­bile de­vices and telemed­i­cine ser­vices.

No­var­tis was an ear­ly in­vestor in Sci­ence 37 and is not new to the idea of vir­tu­al tri­als. No­var­tis owns 10% of Sci­ence 37 af­ter join­ing its $29 mil­lion fi­nanc­ing round with Sanofi, Am­gen, Google, and oth­ers last April.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.